How Common Is Pancreatitis with Ozempic? UK Risk Guide

How common is pancreatitis with Ozempic? Pancreatitis is classified as an 'uncommon' adverse reaction with Ozempic (semaglutide), occurring in approximately 1 in 1,000 to 1 in 100 patients. Ozempic is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus. Whilst pancreatitis remains a recognised potential side effect, the absolute risk is small, and people with type 2 diabetes already have an elevated baseline risk of developing this condition. Understanding the symptoms, risk factors, and when to seek medical attention is essential for safe use of this medication.

Understanding Ozempic and Pancreatitis Risk

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus.^[1][4] It works by mimicking the action of the naturally occurring hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite.^[1][4] These mechanisms help improve glycaemic control and often lead to weight reduction, making Ozempic an effective option for many patients with type 2 diabetes.

Since its introduction, there has been ongoing discussion within the medical community regarding a potential association between GLP-1 receptor agonists and acute pancreatitis. Pancreatitis is inflammation of the pancreas that can range from mild, self-limiting episodes to severe, life-threatening conditions requiring intensive care. The concern arose from pre-clinical animal studies and post-marketing surveillance reports, prompting regulatory bodies including the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) to monitor this potential adverse effect closely.

While evidence regarding a causal relationship remains inconclusive, pancreatitis is listed as a possible side effect in the Ozempic Summary of Product Characteristics (SmPC). The SmPC advises that semaglutide should be discontinued if pancreatitis is suspected. Patients with type 2 diabetes themselves have an elevated baseline risk of pancreatitis compared to the general population, which complicates the assessment of whether any observed cases are directly attributable to the medication or related to underlying metabolic factors and comorbidities.^[6]

It's worth noting that similar pancreatitis warnings apply to semaglutide when used for weight management (Wegovy).

How Common Is Pancreatitis with Ozempic?

In the Ozempic Summary of Product Characteristics (SmPC), acute pancreatitis is listed as an 'uncommon' adverse reaction (occurring in ≥1/1,000 to <1/100 patients).^[1][7] Cases were very infrequent in clinical trials, and real-world post-marketing data have been consistent with these findings.

People with type 2 diabetes have a higher baseline risk of developing pancreatitis compared to the general population.^[6] Large observational studies and meta-analyses examining GLP-1 receptor agonists, including semaglutide, suggest that the absolute risk increase attributable to the medication is small, with no clear increased risk versus comparator treatments.^[20]

It is crucial to interpret these statistics within the broader clinical context. The benefits of improved glycaemic control and weight management often outweigh the small potential risk of pancreatitis for most patients. The SUSTAIN-6 trial showed cardiovascular outcome benefits with semaglutide, though it's important to note that cardiovascular risk reduction is not currently part of Ozempic's UK licence.^[10][11] NICE guidance continues to support the use of semaglutide in appropriate patient populations, emphasising the importance of individualised risk assessment and informed decision-making between patients and their healthcare providers.

Healthcare professionals and patients are encouraged to report any suspected adverse reactions to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk), which helps maintain ongoing surveillance and ensures patient safety remains paramount.

Recognising Symptoms of Pancreatitis

Early recognition of pancreatitis symptoms is essential for prompt diagnosis and management. The hallmark symptom of acute pancreatitis is severe, persistent abdominal pain, typically located in the upper abdomen (epigastric region) and often radiating through to the back. This pain usually develops suddenly and may be described as a constant, boring, or knife-like sensation that worsens after eating, particularly following fatty meals.

Accompanying symptoms frequently include:

• Nausea and vomiting that may be persistent and provide little relief

• Abdominal tenderness and distension, with the abdomen feeling swollen or tight

• Fever and tachycardia as systemic inflammatory responses develop

• Loss of appetite and an inability to tolerate oral intake

• In severe cases, signs of systemic illness such as jaundice, confusion, or shock

Patients taking Ozempic should be counselled to recognise these warning signs. The pain of pancreatitis is typically more severe and persistent than common gastrointestinal side effects associated with GLP-1 receptor agonists, such as mild nausea or dyspepsia, which tend to be transient and improve over time.

If you experience severe, unrelenting abdominal pain whilst taking Ozempic, you should stop the medication immediately and seek urgent medical attention. Do not wait to see if symptoms resolve on their own. Contact your GP urgently, call NHS 111 for advice, or attend your local Emergency Department if symptoms are severe. Timely assessment, including blood tests (serum amylase or lipase levels elevated to at least three times the upper limit of normal) and imaging studies, is necessary to confirm the diagnosis and determine the severity of inflammation, guiding appropriate treatment.^[2]

Risk Factors and Who Should Be Cautious

Certain patient characteristics and medical histories increase the baseline risk of developing pancreatitis, and these factors should be carefully considered before initiating Ozempic therapy. According to the SmPC, semaglutide should be used with caution in patients with a history of pancreatitis. If pancreatitis occurs while on semaglutide therapy, the medication should not be restarted.

Other important risk factors include:

• Gallstones (cholelithiasis), which are the leading cause of acute pancreatitis in the UK^[13]

• Hypertriglyceridaemia, particularly when triglyceride levels exceed 10 mmol/L

• Excessive alcohol consumption, a well-established independent risk factor

• Obesity, which is associated with both gallstone formation and metabolic dysfunction

• Family history of pancreatitis or genetic predisposition

It's also worth noting that GLP-1 receptor agonists, including semaglutide, have been associated with gallbladder disease, which can itself precipitate pancreatitis.^[16][17] Patients should be advised to seek medical attention if they develop symptoms suggestive of gallbladder problems, such as right upper quadrant pain, nausea, or jaundice.

Before prescribing Ozempic, healthcare professionals should conduct a thorough clinical assessment, including a detailed medical history and baseline investigations. NICE guidance (NG28) recommends that lipid profiles, including triglyceride levels, should be monitored in patients with diabetes.^[14] If significant hypertriglyceridaemia is present, this should be addressed before considering GLP-1 receptor agonist therapy.

Patients should be counselled about modifiable risk factors, particularly alcohol intake and weight management. Shared decision-making is essential—discussing both the benefits of improved diabetes control and the small but recognised risk of pancreatitis allows patients to make informed choices about their treatment. For those at higher risk, alternative glucose-lowering therapies may be more appropriate.

What to Do If You Suspect Pancreatitis

If you develop symptoms suggestive of pancreatitis whilst taking Ozempic, immediate action is required. The first step is to discontinue Ozempic and refrain from taking any further doses until you have been assessed by a healthcare professional. Do not attempt to self-manage severe abdominal pain, as pancreatitis can rapidly progress and lead to serious complications including pancreatic necrosis, infection, or multi-organ failure.

Seek urgent medical attention through one of the following routes:

• Contact your GP practice immediately for same-day assessment if symptoms develop during working hours

• Call NHS 111 for guidance if you are unsure about the severity or need advice outside normal surgery hours

• Attend your local Emergency Department or call 999 if you experience severe pain, persistent vomiting, signs of dehydration, fever, or feel generally unwell

When you present for medical assessment, inform healthcare staff that you are taking Ozempic and describe your symptoms clearly. Diagnosis typically involves blood tests measuring serum amylase or lipase levels (elevated to at least three times the upper limit of normal), alongside imaging studies such as abdominal ultrasound or CT scanning to visualise pancreatic inflammation and identify potential complications.^[2]

Management of acute pancreatitis is primarily supportive and usually requires hospital admission. Treatment includes intravenous fluid resuscitation, pain relief, anti-emetics, and nutritional support. Most cases resolve with conservative management, though severe pancreatitis may necessitate intensive care.

It's important to monitor your blood glucose levels after stopping Ozempic and contact your diabetes team for advice on adjusting your diabetes treatment regimen.

Following a confirmed episode of pancreatitis, Ozempic should not be restarted, as stated in the SmPC.^[1][15] Your diabetes care team will need to review your treatment plan and consider alternative glucose-lowering therapies. It is essential to attend follow-up appointments to ensure your diabetes remains well controlled and to address any underlying risk factors that may have contributed to the pancreatitis episode.

Scientific References

1. Ozempic 0.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics (emc).
2. Pancreatitis (NG104) – NICE.
3. Semaglutide: a medicine to manage type 2 diabetes or treat obesity – NHS.
4. Ozempic – European Medicines Agency (EMA) EPAR.
5. Semaglutide – BNF (NICE).
6. Increased risk of acute pancreatitis and biliary disease observed in patients with diabetes – PubMed 19208917.
7. Ozempic EPAR product information (PDF) – EMA.
8. MHRA updates guidance for semaglutide prescribers and patients – GOV.UK.
9. GLP-1 medicines for weight loss and diabetes: what you need to know – GOV.UK.
10. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) – N Engl J Med 2016.
11. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) – PubMed 27633186.
12. MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults – GOV.UK.
13. Pancreatitis (NG104) – Context chapter – NICE.
14. Type 2 diabetes in adults: management (NG28) – NICE.
15. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases – MHRA Drug Safety Update.
16. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases – JAMA Intern Med.
17. Safety of Semaglutide – Frontiers in Endocrinology. PubMed 34305810.
18. Wegovy 1 mg FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics (emc).
19. Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis – JAMA Intern Med.
20. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials – Endocrinol Diabetes Metab. PubMed 40988099.

Frequently Asked Questions